THE LEUKOTRIENE RECEPTOR ANTAGONIST, PRANLUKAST, INHIBITS EXERCISED-INDUCED BRONCHOSPASM (EIB) IN ASTHMATIC CHILDREN

Abstract

The purpose of this study was to determine whether pranlukast, a leukotriene receptor antagonist, attenuates exercise-induced bronchospasm (EIB) in children with asthma. Study design was a randomized multicenter doubled-blind placebo-controlled 2-period crossover trial.
Subjects were 17 stable asthmatic children aged 7 to 14 years (mean: 11.0 years) with a history of typical symptoms of EIB. They received dry syrup of pranlukast or placebo both after dinner in the first day and after breakfast in the second day in each period. For each patient, all exercise challenges were performed on a bicycle ergometer and spirometry measurements were collected pre-and post-exercise.
In conclusion, pranlukast, compared with placebo, significantly inhibited the reduction of pulmonary function after exercise, which was estimated by spirometry measurements (FVC, FEV_1.0, PEF, MMF, V₅₀ and V₂₅). This study demonstrated that pranlukast, a leukotriene receptor antagonist, is a useful drug in asthma management.